ct-868

Type 1 Diabetes Mellitus

Carmot Therapeutics, Inc.UNKNOWNPhase 2Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

8 Active assets in the Type 1 Diabetes Mellitus cohort.

Asset / Sponsor	Phase	Rating
Metformin Heba M. Ismail	Phase 4	A
Liraglutide Dasman Diabetes Institute	Phase 4	BBB
Tirzepatide Royal North Shore Hospital	Phase 4	BBB
Semaglutide Nordsjaellands Hospital	Phase 3	BB
.Alpha.-1 Protease Inhibitor Grifols Therapeutics LLC	Phase 2	B

View all 21 →

Same molecule, other indications

ct-868 is also rated in:

obesity disorderActive

B

Indicative · Phase 2

62 / 100

type 2 diabetes mellitusActive

B

Indicative · Phase 2

57 / 100

diabetes mellitusDormant

CC

Indicative · Phase 1

44 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.